Utvidelse av SpinChip plattformen innen akuttmedisin

Offentlig prosjektsammendrag

SpinChip Diagnostics AS, which since January 2025 is a wholly owned subsidiary of bioMérieux, is developing a groundbreaking point-of-care diagnostic platform consisting of a compact, fully automated instrument and single-use analysis cartridges with integrated reagents. The system enables advanced blood analyses to be performed rapidly and easily using just a drop of blood, with analytical performance comparable to high-end laboratory instruments. The current project marks a new phase in the industrialization and expansion of the SpinChip platform. It includes completing clinical validation of the first test, a high-sensitivity cardiac troponin I (hs-cTnI) assay and analyzer, as well as development of new emergency care assays to broaden the platform’s clinical utility. In parallel, multiplex test formats and concepts beyond immunoassays will be explored.